Citicoline & Antioxidants in Glaucoma

Effect of Oral Citicoline, Vitamins A, B, C and E, and Blackcurrant in Primary Open-Angle Glaucoma With OCT and Angiography

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06355765

Enrollment

Registered

2024-04-09

Start date

2022-01-10

Completion date

2022-12-10

Last updated

2024-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Open-Angle

Brief summary

To evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) using optical coherence tomography (OCT), OCT angiography (OCTA) and microperimetry parameters.

Detailed description

AIMS: To evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) using optical coherence tomography (OCT), OCT angiography (OCTA) and microperimetry parameters. METHODS: Fifteen patients with POAG (treated group) received one soluble liquid sachet daily for 20 days a month of a complementary dietary supplement containing in fixed combination citicoline, vitamins A, B, C, and E, and blackcurrant for 1 year. Fifteen age-matched subjects affected by POAG were given a placebo and served as a control group. The patients underwent best corrected visual acuity (BCVA), Goldmann applanation tonometry, microperimetry examination, OCT, and OCTA at the beginning of the study and then at 1, 6 and 12 months.

Interventions

DIETARY_SUPPLEMENTCiticoline blackcurrant supplement

Citicoline, Vitamins A, B, C and E, and Blackcurrant

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 90 Years

Inclusion criteria

* diagnosis of POAG * aged between 18 and 75 years * Patients with controlled intraocular pressure (IOP) below 20 mmHg, who had been on the same topical hypotensive therapy for at least 3 months * myopia less than 5 diopters (D) were considered eligible for inclusion.

Exclusion criteria

* IOP levels exceeding 21 mmHg, * hyper-sensitivity to citicoline, * a history of optic neuritis, * previous glaucoma or retinal surgery, * prior cataract or refractive surgery, * macular degeneration or other retinal disorders, * any systemic diseases that could potentially lead to neurodegeneration (e.g., multiple sclerosis, diabetes)

Design outcomes

Primary

Measure	Time frame	Description
Evaluation of Ganglionar cells complex (GCC)	From enrollment to the end of treatment at 1 year	evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) on GCC using optical coherence tomography (OCT)

Secondary

Measure	Time frame	Description
Evaluation of Retinal nerve fiber layer (RNFL)	From enrollment to the end of treatment at 1 year	evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) on RNFL using optical coherence tomography (OCT)

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026